This lesson addresses a different category of challenge entirely. Here, the question is not who can consent but whether the standard consent process can happen at all. Two situations push past the boundaries of the ordinary process: when the participant cannot read the consent document in the language in which it was written, and when there is no time to obtain consent before a life-saving intervention must begin.

Both situations have regulatory solutions. The short-form consent process, codified in 21 CFR 50.27(b), addresses the first. The emergency consent exception, outlined in ICH E6(R3) Section 2.8.8 and further specified in FDA regulations at 21 CFR 50.24, addresses the second. And both solutions are, in my experience, among the most frequently misunderstood mechanisms in the informed consent landscape. I have reviewed audit findings and inspection reports where sites used the short-form process as a convenience shortcut, and where emergency consent exceptions were invoked without the pre-approval infrastructure the regulation requires.

These are exception mechanisms -- safety valves built into the regulatory system for situations the standard process was not designed to handle. They are not shortcuts. They are not workarounds. They carry their own documentation requirements that are, if anything, more demanding than the standard process. This lesson will teach you when to use them, how to execute them correctly, and why the details matter.

This lesson addresses a different category of challenge entirely. Here, the question is not who can consent but whether the standard consent process can happen at all. Two situations push past the boundaries of the ordinary process: when the participant cannot read the consent document in the language in which it was written, and when there is no time to obtain consent before a life-saving intervention must begin.

Both situations have regulatory solutions. The short-form consent process, codified in 21 CFR 50.27(b), addresses the first. The emergency consent exception, outlined in ICH E6(R3) Section 2.8.8 and further specified in FDA regulations at 21 CFR 50.24, addresses the second. And both solutions are, in my experience, among the most frequently misunderstood mechanisms in the informed consent landscape. I have reviewed audit findings and inspection reports where sites used the short-form process as a convenience shortcut, and where emergency consent exceptions were invoked without the pre-approval infrastructure the regulation requires.

These are exception mechanisms -- safety valves built into the regulatory system for situations the standard process was not designed to handle. They are not shortcuts. They are not workarounds. They carry their own documentation requirements that are, if anything, more demanding than the standard process. This lesson will teach you when to use them, how to execute them correctly, and why the details matter.